Market Place
Sourcing Support
SpliSense Gets FDA Fast Track For SPL84 In Cystic Fibrosis
30 May 2024 //
PR NEWSWIRE
SpliSense Announces FDA Clearance of IND App for Ph 2 Initiation of SPL84
03 Apr 2024 //
PR NEWSWIRE
CF Foundation Provides Up to $8.5M to SpliSense to Support a Clinical Trial
03 Apr 2024 //
BUSINESSWIRE
SpliSense Successfully Completed Phase 1 Study of SPL84
06 Sep 2023 //
PR NEWSWIRE
SpliSense begins Phase I/II trial of SPL84 for cystic fibrosis
15 Dec 2022 //
CLINICALTRIALSARENA
SpliSense Initiates Phase 1/2 Study of SPL84, RNA-Based Therapy
14 Dec 2022 //
PRNEWSWIRE
SpliSense Announces FDA and EMA Grant ODD to SPL84-23-1
04 Jan 2022 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.